Related Experiment Video

Updated: Aug 30, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Inflammation and restenosis: implications for therapy

Marjo M P C Donners1, Mat J A P Daemen, Kitty B J M Cleutjens

  • 1Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, the Netherlands.

Annals of Medicine
|December 3, 2003
PubMed

Insights

Inflammation, driven by cytokines, plays a key role in restenosis, the arterial narrowing after stenting. Immunosuppressive therapies show promise for treating this condition.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Medical Interventions

Background:

  • Restenosis involves arterial narrowing post-intervention, primarily attributed to smooth muscle cell activity.
  • Emerging evidence highlights inflammation and cytokines as critical drivers of restenosis development.
  • Understanding restenosis molecular mechanisms is vital for effective therapeutic strategies.

Purpose of the Study:

  • To review the molecular mechanisms underlying restenosis.
  • To emphasize the role of inflammation in restenosis pathogenesis.
  • To discuss the therapeutic potential of immunosuppressive agents.

Main Methods:

  • Literature review focusing on molecular mechanisms of restenosis.
  • Analysis of studies investigating inflammatory mediators (cytokines) in restenosis.
  • Evaluation of research on immunosuppressive therapies for restenosis treatment.

Main Results:

  • Inflammation, mediated by cytokines, is increasingly recognized as a central factor in restenosis.
  • Drug-eluting stents utilizing immunosuppressives have demonstrated significant efficacy in managing restenosis.
  • Molecular insights into restenosis pave the way for targeted anti-inflammatory treatments.

Conclusions:

  • Inflammation is a key regulator of restenosis, involving cytokines and smooth muscle cell proliferation.
  • Immunosuppressive therapy, particularly in drug-eluting stents, offers a promising approach to combat restenosis.
  • Further research into inflammatory pathways can lead to improved treatments for preventing arterial narrowing after interventions.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...